Antiepileptic drugs used in childhood. New products and new concepts;Fármacos antiepilépticos utilizados en la infancia. Nuevos productos y nuevos conceptos

Anales de Pediatria

Volumn 58, Issue 2, 2003, Pages 136-145

  Garaizar Axpe, C ^a   Villaverde Bello, A ^a   Perez Concha T ^a   Herrera Isasi, M ^a   Alvarez Ruiz de Larrinaga A ^a  

^a HOSPITAL DE CRUCES   (Spain)

Author keywords

Antiepileptic drugs; Gabapentin; Lamotrigine; Levetiracetam; Oxcarbazepine; Tiagabine; Topiramate; Vigabatrin

Indexed keywords

ACETAZOLAMIDE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLORAMPHENICOL; CIMETIDINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ERYTHROMYCIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUOXETINE; GABAPENTIN; ISONIAZID; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VERAPAMIL; VIGABATRIN;

ABSENCE; ANTICONVULSANT THERAPY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SAFETY; EPILEPSY; FIRST PASS EFFECT; FOCAL EPILEPSY; FOOD AND DRUG ADMINISTRATION; GRAND MAL SEIZURE; HUMAN; LENNOX GASTAUT SYNDROME; MYOCLONUS SEIZURE; PETIT MAL; PHARMACODYNAMICS; PHARMACOGENETICS; REVIEW; SPAIN; TONIC CLONIC SEIZURE; WEST SYNDROME;

EID: 0038407590     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042978     Document Type: Review

References (29)

1. Walker MC, White HS, Sander JW. Disease modification in partial epilepsy. Brain 2002;125(Pt 9):1937-50.
2. Temkin NR, Jarell AD, Anderson GD. Antiepileptic agents: How close are we? Drugs 2001;61:1045-55.
3. Cereghino JJ, Penry K. Introduction. En: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs, 4th ed. Philadelphia: Lippincott-Raven, 1996.
4. Loscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2001;23:113-8.
5. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for a revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
6. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
7. Engel J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42:796-803.
8. Guerrini R, Arzimanoglou A, Brouwer O. Rationale for treating epilepsy in children. Epileptic Disorders 2002;4(Suppl 2):S9-S21.
9. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: Reexamining its role in the treatment of epilepsy. Epilepsia 2000;41(Suppl 8):S6-S15.
10. Perucca E, Richens A. General Principles. Biotransformation. En: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs, 4th ed. Philadelphia: Lippincott-Raven, 1996.
11. Browne TR. Pharmacokinetics of antiepileptic drugs. Epilepsia 1998;51(Suppl 4):S2-S7.
12. Dichter MA. Mechanisms of action of new antiepileptic drugs. Adv Neurol 1998;76:1-9.
13. French JA, Gidal BE. Antiepileptic drugs interactions. Epilepsia 2000;41(Suppl 8):S30-S36.
14. McInnes GT, Brodie MJ. Drug interactions that matter. A critical reappraisal. Drugs 1998;36:83-110.
15. Patsalos PN, Duncan JS. Antiepileptic drugs. A review of clinical significant drug interactions. Drug Safety 1993;9:156-84.
16. Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia 2000;41(Suppl 2):S42-S52.
17. Bourgeois B. New dosages and formulations of AEDs for use in pediatric epilepsy. Neurology 2002;58(Suppl 7):S2-S5.
18. Glausser TA. Idiosyncratic reactions: New methods of identifying high-risk patients. Epilepsia 2000;41(Suppl 8):S16-S29.
19. Wilmore LJ, Triggs WJ, Pellock JM. Valproate toxicity: Risk screening strategies. J Child Neurol 1991;6:3-6.
20. Spear BB. Pharmacogenetics and antiepileptic drugs. Epilepsia 2001;42(Suppl 5):31-4.
21. Sisodiya SM, Lin WR, Harding BN, Squier ML, Thom M. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002;125(Pt 1):22-31.
22. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(Suppl 5):S2-S8.
23. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: A systematic review of their efficacy and tolerability. BMJ 1996;313:1169-74.
24. Privitera MD. Evidence-based medicine and antiepileptic drugs. Epilepsia 1999;40(Suppl 5):S47-S56.
25. Brodie MJ. Management strategies for refractory localization-related seizures. Epilepsia 2001;42(Suppl 3:S27-S30.
26. Guidelines for antiepileptic drug trials in children. Commission on Antiepileptic Drugs of the International League Against Epilepsy. Epilepsia 1994;35:94-100.
27. Pellock JM. Pediatric Trials: Practical issues. Special populations and trial design. Adv Neurol 1998;76:167-71.
28. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995;95:286-94.
29. Glauser TA. Integrating clinical trial data into clinical practice. Neurology 2002;58(Suppl 7):S6-S12.